TLSA ▲ +2.9% - Tiziana Life Sciences Ltd $TLSA - Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease 16-OCT-2026 07:00 AM ET